Cargando…
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy
With 185 million people chronically infected globally, hepatitis C is a leading bloodborne infection. All-oral regimens of direct acting agents have superior efficacy compared to the historical interferon-based regimens and are significantly more tolerable. However, trials of both types of regimens...
Autores principales: | Ooka, Kohtaro, Lim, Joseph K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075004/ https://www.ncbi.nlm.nih.gov/pubmed/27777889 http://dx.doi.org/10.14218/JCTH.2016.00017 |
Ejemplares similares
-
Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
por: Connolly, James J., et al.
Publicado: (2018) -
Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update
por: Stasi, Cristina, et al.
Publicado: (2021) -
The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation
por: Albekairy, Abdulkareem M., et al.
Publicado: (2018) -
Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy
por: Lee, Hae Lim, et al.
Publicado: (2017) -
New Immunosuppressive Therapies in Uveitis Treatment
por: Mérida, Salvador, et al.
Publicado: (2015)